Bis(thiosemicarbazone) Complexes of Cobalt(III). Synthesis, Characterization, and Anticancer Potential.

Nine bis(thiosemicarbazone) (BTSC) cobalt(III) complexes of the general formula [Co(BTSC)(L)2]NO3 were synthesized, where BTSC = diacetyl bis(thiosemicarbazone) (ATS), pyruvaldehyde bis(thiosemicarbazone) (PTS), or glyoxal bis(thiosemicarbazone) (GTS) and L = ammonia, imidazole (Im), or benzylamine (BnA). These compounds were characterized by multinuclear NMR spectroscopy, mass spectrometry, cyclic voltammetry, and X-ray crystallography. Their stability in phosphate-buffered saline was investigated and found to be highly dependent on the nature of the axial ligand, L. These studies revealed that complex stability is primarily dictated by the axial ligand following the sequence NH3 > Im > BnA. The cellular uptake and cytotoxicity in cancer cells were also determined. Both the cellular uptake and cytotoxicity were significantly affected by the nature of the equatorial BTSC. Complexes of ATS were taken up much more effectively than those of PTS and GTS. The cytotoxicity of the complexes was correlated to that of the free ligand. Cell uptake and cytotoxicity were also determined under hypoxic conditions. Only minor differences in the hypoxia activity and uptake were observed. Treatment of the cancer cells with the copper-depleting agent tetrathiomolybdate decreased the cytotoxic potency of the complexes, indicating that they may operate via a copper-dependent mechanism. These results provide a structure-activity relationship for this class of compounds, which may be applied for the rational design of new cobalt(III) anticancer agents.

[1]  T. Storr,et al.  Cobalt(III) complexes with 2-acetylpyridine-derived Schiff bases: Studies investigating ligand release upon reduction , 2017 .

[2]  S. Radulović,et al.  (Chalcogen)semicarbazones and their cobalt complexes differentiate HL-60 myeloid leukaemia cells and are cytotoxic towards tumor cell lines. , 2017, MedChemComm.

[3]  C. Parkinson,et al.  Cytotoxic activity of expanded coordination bis-thiosemicarbazones and copper complexes thereof , 2016, JBIC Journal of Biological Inorganic Chemistry.

[4]  M. Hemann,et al.  The Potent Inhibitory Effect of a Naproxen‐Appended Cobalt(III)‐Cyclam Complex on Cancer Stem Cells , 2016, Chembiochem : a European journal of chemical biology.

[5]  V. Ferreira,et al.  Investigation of cobalt(iii)-triazole systems as prototypes for hypoxia-activated drug delivery. , 2016, Dalton transactions.

[6]  D. Richardson,et al.  Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity. , 2016, Journal of medicinal chemistry.

[7]  A. Banerjee,et al.  Exploiting Copper Redox for (19)F Magnetic Resonance-Based Detection of Cellular Hypoxia. , 2016, Journal of the American Chemical Society.

[8]  D. Richardson,et al.  Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization. , 2015, Journal of inorganic biochemistry.

[9]  Nicole S. Bryce,et al.  Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells. , 2015, Chemistry.

[10]  Marie C. Heffern,et al.  Tuning cobalt(III) Schiff base complexes as activated protein inhibitors. , 2015, Inorganic chemistry.

[11]  K. Suntharalingam,et al.  Advances in cobalt complexes as anticancer agents. , 2015, Dalton transactions.

[12]  D. Richardson,et al.  Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)* , 2015, The Journal of Biological Chemistry.

[13]  G. Sheldrick SHELXT – Integrated space-group and crystal-structure determination , 2015, Acta crystallographica. Section A, Foundations and advances.

[14]  A. McEwan,et al.  Inhibition of respiratory complex I by copper(ii)-bis(thiosemicarbazonato) complexes. , 2014, Metallomics : integrated biometal science.

[15]  A. Renfrew,et al.  Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. , 2014, Metallomics : integrated biometal science.

[16]  S. Gaudet,et al.  Cell-to-cell variability in cell death: can systems biology help us make sense of it all? , 2014, Cell Death and Disease.

[17]  Ahmed Rezk,et al.  Cytotoxic behavior and spectroscopic characterization of metal complexes of ethylacetoacetate bis(thiosemicarbazone) ligand. , 2014, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[18]  S. Allison,et al.  Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors , 2014, British journal of pharmacology.

[19]  Justin J. Wilson,et al.  Synthetic methods for the preparation of platinum anticancer complexes. , 2013, Chemical reviews.

[20]  Mohammad Fallahi-Sichani,et al.  Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.

[21]  Nicole S. Bryce,et al.  Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study , 2013 .

[22]  Mårten Fryknäs,et al.  Effects of hypoxia on human cancer cell line chemosensitivity , 2013, BMC Cancer.

[23]  W. Denny,et al.  Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs. , 2013, Inorganic chemistry.

[24]  Justin J. Wilson,et al.  Monofunctional and higher-valent platinum anticancer agents. , 2013, Inorganic chemistry.

[25]  Marie C. Heffern,et al.  Cobalt derivatives as promising therapeutic agents. , 2013, Current opinion in chemical biology.

[26]  K. Somasundaram,et al.  In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes. , 2013, Journal of medicinal chemistry.

[27]  Marie C. Heffern,et al.  Axial ligand exchange of N-heterocyclic cobalt(III) Schiff base complexes: molecular structure and NMR solution dynamics. , 2013, Inorganic chemistry.

[28]  Nicole S. Bryce,et al.  Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex. , 2012, Journal of medicinal chemistry.

[29]  S. Lippard,et al.  Redox activation of metal-based prodrugs as a strategy for drug delivery. , 2012, Advanced drug delivery reviews.

[30]  J. Dilworth,et al.  Metal Complexes of Thiosemicarbazones for Imaging and Therapy , 2012 .

[31]  Marie C. Heffern,et al.  Specific inhibition of the transcription factor Ci by a cobalt(III) Schiff base-DNA conjugate. , 2012, Molecular pharmaceutics.

[32]  P. Crouch,et al.  An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copperII , 2011, Proceedings of the National Academy of Sciences.

[33]  R. Gillies,et al.  Drug resistance and cellular adaptation to tumor acidic pH microenvironment. , 2011, Molecular pharmaceutics.

[34]  Nicole S. Bryce,et al.  Visualising the hypoxia selectivity of cobalt(III) prodrugs , 2011 .

[35]  P. Crouch,et al.  Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes. , 2011, Inorganic chemistry.

[36]  P. Donnelly,et al.  Copper Complexes of Bis(thiosemicarbazones): From Chemotherapeutics to Diagnostic and Therapeutic Radiopharmaceuticals , 2011 .

[37]  W. Berger,et al.  Anticancer activity of metal complexes: involvement of redox processes. , 2011, Antioxidants & redox signaling.

[38]  D. Richardson,et al.  Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. , 2011, Cancer research.

[39]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[40]  W. Denny,et al.  Syntheses of 8-quinolinolatocobalt(III) complexes containing cyclen based auxiliary ligands as models for hypoxia-activated prodrugs. , 2010, Dalton transactions.

[41]  John E. Bercaw,et al.  NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist , 2010 .

[42]  D. Richardson,et al.  Thiosemicarbazones: the new wave in cancer treatment. , 2009, Future medicinal chemistry.

[43]  T. Meade,et al.  Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate , 2009, Proceedings of the National Academy of Sciences.

[44]  P. Müller Practical suggestions for better crystal structures , 2009 .

[45]  T. Hambley Physiological Targeting to Improve Anticancer Drug Selectivity , 2008 .

[46]  A. Argyriou,et al.  A review on oxaliplatin-induced peripheral nerve damage. , 2008, Cancer treatment reviews.

[47]  Q. Le,et al.  Clinical biomarkers for hypoxia targeting , 2008, Cancer and Metastasis Reviews.

[48]  B. Keppler,et al.  Electron-transfer activated metal-based anticancer drugs , 2008 .

[49]  Trevor W. Hambley,et al.  Cellular uptake and distribution of cobalt complexes of fluorescent ligands , 2008, JBIC Journal of Biological Inorganic Chemistry.

[50]  A. G. Wedd,et al.  Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity. , 2008, Inorganic chemistry.

[51]  R. Gust,et al.  Cellular uptake quantification of metalated peptide and peptide nucleic acid bioconjugates by atomic absorption spectroscopy. , 2008, Angewandte Chemie.

[52]  Jason S. Lewis,et al.  Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. , 2007, Dalton transactions.

[53]  M. Hall,et al.  Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. , 2007, Dalton transactions.

[54]  K. Nugent,et al.  Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.

[55]  D. Richardson,et al.  Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. , 2006, Journal of medicinal chemistry.

[56]  J. Yi,et al.  Synthesis and crystal structure of some transition metal complexes with a novel bis-Schiff base ligand and their antitumor activities. , 2006, European journal of medicinal chemistry.

[57]  Mika Kettunen,et al.  Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. , 2006, Current medicinal chemistry.

[58]  C. Ling,et al.  Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. , 2005, Nuclear medicine and biology.

[59]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[60]  L. Helm,et al.  Inorganic and bioinorganic solvent exchange mechanisms. , 2005, Chemical reviews.

[61]  R. Gust,et al.  Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics. , 2004, Journal of medicinal chemistry.

[62]  C. Reynolds,et al.  Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. , 2002, Journal of medicinal chemistry.

[63]  Jason S. Lewis,et al.  Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships , 2002, JBIC Journal of Biological Inorganic Chemistry.

[64]  Nobuyuki Oyama,et al.  Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells , 2001, Annals of nuclear medicine.

[65]  A. W. Addison,et al.  Conversion constants for redox potentials measured versus different reference electrodes in acetonitrile solutions at 25°C , 2000 .

[66]  M. McKeage,et al.  Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. , 1999, Journal of inorganic biochemistry.

[67]  H. Gray,et al.  Inhibition of thermolysin and human α-thrombin by cobalt(III) Schiff base complexes , 1999 .

[68]  M. Simon,et al.  Selective Inhibition of Human α-Thrombin by Cobalt(III) Schiff Base Complexes , 1998 .

[69]  E. Cvitkovic Cumulative toxicities from cisplatin therapy and current cytoprotective measures. , 1998, Cancer treatment reviews.

[70]  L. Frydman,et al.  Solid and liquid phase 59Co NMR studies of cobalamins and their derivatives. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[71]  H. Gray,et al.  Spectroscopy and Electrochemistry of Cobalt(III) Schiff Base Complexes , 1997 .

[72]  Neil G. Connelly,et al.  Chemical Redox Agents for Organometallic Chemistry. , 1996, Chemical reviews.

[73]  A. Yamasaki Cobalt-59 Nuclear Magnetic Resonance Spectroscopy in Coordination Chemistry , 1991 .

[74]  A. B. P. Lever,et al.  Electrochemical parametrization of metal complex redox potentials, using the ruthenium(III)/ruthenium(II) couple to generate a ligand electrochemical series , 1990 .

[75]  G. Navon,et al.  Spectroscopic and solution properties of the cobalt(III) hexaimidazole ion , 1989 .

[76]  J. Mason Patterns of nuclear magnetic shielding of transition-metal nuclei , 1987 .

[77]  M. Lemmon,et al.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. , 1986, International journal of radiation oncology, biology, physics.

[78]  M. Brorson,et al.  Cobalt-59 NMR chemical shifts of cobalt(III) complexes; correlations with parameters calculated from ligand-field spectra , 1985 .

[79]  C. H. Bayley,et al.  THE PREPARATION OF SOME THIOSEMICARBAZONES AND THEIR COPPER COMPLEXES: PART III , 1960 .

[80]  B. L. Freedlander,et al.  Carcinostatic action of polycarbonyl compounds and their derivatives. IV. Glyoxal bis (thiosemicarbazone) and derivatives. , 1958, Cancer research.

[81]  S. Williamson,et al.  Tirapazamine: a novel agent targeting hypoxic tumor cells. , 2009, Expert opinion on investigational drugs.

[82]  M. Jakupec,et al.  Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. , 2009, Journal of analytical atomic spectrometry.

[83]  G. Sheldrick A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[84]  G. Daugaard,et al.  Cisplatin nephrotoxicity , 2004, Cancer Chemotherapy and Pharmacology.

[85]  S. Merajver,et al.  Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  Jason S. Lewis,et al.  Redox-active metal complexes for imaging hypoxic tissues: structure–activity relationships in copper(II) bis(thiosemicarbazone) complexes , 1998 .

[87]  M Iturralde Navarro,et al.  [Culture of animal cells]. , 1984, Medicina clinica.

[88]  E. Blanz,et al.  Chemotherapy studies on transplanted mouse tumors. VIII. , 1963, Cancer research. Supplement.

[89]  B. L. Freedlander Chemotherapy studies on transplanted mouse tumors. , 1955, Cancer research.

[90]  R. J. P. Williams,et al.  637. The stability of transition-metal complexes , 1953 .